Hepion Pharmaceuticals Current Valuation vs. Short Ratio
| HEPA Stock | USD 0.69 0.01 1.47% |
For Hepion Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hepion Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hepion Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hepion Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hepion Pharmaceuticals over time as well as its relative position and ranking within its peers.
Hepion |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.40) | Return On Assets (0.93) | Return On Equity (1.90) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Hepion Pharmaceuticals Short Ratio vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Hepion Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hepion Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Hepion Pharmaceuticals is rated # 3 in current valuation category among its peers. It is rated # 5 in short ratio category among its peers . The ratio of Current Valuation to Short Ratio for Hepion Pharmaceuticals is about 7,883,612 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hepion Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Hepion Current Valuation vs. Competition
Hepion Pharmaceuticals is rated # 3 in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 141.34 Million. Hepion Pharmaceuticals holds roughly 7.25 Million in current valuation claiming about 5% of equities under Health Care industry.
Hepion Short Ratio vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Hepion Pharmaceuticals |
| = | 7.25 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Hepion Pharmaceuticals |
| = | 0.92 X |
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
Hepion Short Ratio Comparison
Hepion Pharmaceuticals is currently under evaluation in short ratio category among its peers.
Hepion Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Hepion Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hepion Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Hepion Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Hepion Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -78.8 K | -74.8 K | |
| Operating Income | -48.4 M | -46 M | |
| Income Before Tax | -49.3 M | -46.9 M | |
| Total Other Income Expense Net | -887.1 K | -842.8 K | |
| Net Loss | -48.9 M | -46.5 M | |
| Income Tax Expense | 409 K | 429.5 K | |
| Net Loss | -40.8 M | -38.8 M | |
| Interest Income | 158.3 K | 150.4 K | |
| Net Loss | -44.7 M | -42.4 M | |
| Net Interest Income | -9.6 K | -10 K | |
| Change To Netincome | 4.6 M | 4.8 M | |
| Net Loss | (12.32) | (12.94) | |
| Income Quality | 0.84 | 0.66 | |
| Net Income Per E B T | 0.99 | 0.74 |
Hepion Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Hepion Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hepion Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hepion Pharmaceuticals' important profitability drivers and their relationship over time.
Use Hepion Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hepion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hepion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Hepion Pharmaceuticals Pair Trading
Hepion Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Hepion Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hepion Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hepion Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hepion Pharmaceuticals to buy it.
The correlation of Hepion Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hepion Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hepion Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hepion Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Hepion Pharmaceuticals position
In addition to having Hepion Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Oil And Gas Thematic Idea Now
Oil And Gas
Companies involved in drilling, production, and distribution of oil and gas pipelines. The Oil And Gas theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Oil And Gas Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
To fully project Hepion Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Hepion Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Hepion Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.